Andere Sprachen Passage Bio, Inc.

Aktien

A2P0EQ

US7027121000

PASG

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
1,32 ^USD	+8,20 %		+14,78 %	+30,69 %

04.03.	Passage Bio, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI
2023	Passage Bio sagt, dass die Daten aus der Phase 1/2-Studie zur Demenztherapie die Erwartungen übertroffen haben	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

PASSAGE BIO TO PRESENT AT CHARDAN'S 8TH ANNUAL GENETIC MEDICINES AND CELL THERAPY MANUFACTURING SUMMIT	23.04.
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit	22.04.
Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program	05.03.
Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04.03.
Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer	04.03.
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights	04.03.
Passage Bio to Participate in Upcoming Investor Conferences	27.02.
Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31.01.
Passage Bio : IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE - Form 8-K	29.12.
Passage Bio Says Data From Phase 1/2 Trial of Dementia Therapy Exceeded Expectations	20.12.
Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities	20.12.
Passage Bio, Inc. Announces Promising Initial Data from Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities	20.12.
Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)	17.11.
Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights	13.11.
Passage Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13.11.
Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference	30.10.23
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20.10.23
Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20.10.23
Metachromatic Leukodystrophy Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	09.10.23
Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference	25.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Passage Bio, Inc.

Aktien

A2P0EQ

US7027121000

PASG

Andere Sprachen

Filter